3 news items
Rhythm Pharmaceuticals Receives Positive Recommendation from NICE for ▼IMCIVREE® (setmelanotide) for Treatment of Obesity and Hyperphagia in Patients with Bardet-Biedl Syndrome
RYTM
22 May 24
to benefit from therapy. "Access to IMCIVREE in England and Wales is an important milestone in our global efforts to bring this medicine
Rhythm Pharmaceuticals to Report First Quarter 2024 Financial Results on Tuesday, May 7, 2024
RYTM
24 Apr 24
and provide a corporate update. To access the live conference call, participants may register
Navigating Interest Rate Speculations and M&A Trends with a Spotlight on Actinium Pharmaceuticals (ATNM)
ATNM
AZN
BMY
18 Apr 24
BMT access and engagement. Click HERE to read more
- Prev
- 1
- Next